Dyne Therapeutics, Inc.

$18.23

$-0.27 (-1.46%)

Jan 5, 2026

Price History (1Y)

Analysis

Dyne Therapeutics, Inc. is a biotechnology company listed in the healthcare sector with a market capitalization of $3.00B and approximately 240 employees. The company's financial health indicates significant losses, with net income of -$423,800,992 and EBITDA of -$447,184,992 (TTM). The gross margin, operating margin, and profit margin are all 0.0%. Returns on equity and assets are also negative at -60.7% and -34.3%, respectively. The balance sheet shows a debt-to-equity ratio of 17.41 and cash of $791.89M with debt of $120.47M. The valuation context for Dyne Therapeutics is marked by a forward P/E ratio of -5.50, which is not indicative of the company's growth prospects or profitability. The price to book ratio is 3.76, but revenue and earnings growth rates are not available. Dividend yield is also not applicable due to the absence of dividend payments.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Visit website →

Key Statistics

Market Cap
$3.00B
P/E Ratio
N/A
52-Week High
$25.00
52-Week Low
$6.36
Avg Volume
2.89M
Beta
1.32

Company Info

Exchange
NMS
Country
United States
Employees
240